DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

DRG and its group companies would like to inform you that we have updated our website privacy policy.

Acknowledge
New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here
› › China In-Depth

China In-Depth

Help your business succeed in the lucrative Chinese pharmaceutical market through DRG’s China In-Depth comprehensive data and insights. Assess commercial opportunities and optimize your strategy in China for nearly twenty key indications:

China In-Depth 2020 Coverage

  • Acute Myeloid Leukemia
  • NSCLC
  • Hepatitis B Virus
  • Psoriasis
  • Heart Failure
  • Non-Hodgkin’s Lymphoma
  • Breast Cancer
  • Migraine
  • Gastric Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Atopic Dermatitis
  • Biosimilars in China

China In-Depth 2019 Coverage

  • Non-Small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • Rheumatoid Arthritis
  • Non-Alcoholic Fatty Liver Disease
  • Multiple Sclerosis
  • Type 2 Diabetes
  • Gastric Cancer
  • Colorectal Cancer
  • Bladder Cancer

We have prioritized these indications based on China’s epidemiology landscape, clinical unmet needs, and commercial opportunities. Our solution features broad, deep, and geographically diverse primary market research with five thought-leading physician interviews and 50 physician surveys per indication.

Gain Insights

Key Features

  • World-class epidemiology, including rural and urban populations
  • Keen insight into the complex access and reimbursement environment, including NRDL updates and volume-based procurement (VBP) programs
  • Deeper understanding of current treatment paradigms including interviews with Chinese physicians
  • In-depth early stage and late stage pipeline coverage
  •  10-year, annualized, drug-level forecasts split between brand versus generic/biosimilar sales, supported by detailed primary and secondary research
China represents a $140 billion pharmaceutical market–the second largest in the world–with rapid growth projected in the years to come. Although national insurance coverage has broadened and regulatory pathways have become more streamlined, enormous differences remain between China’s urban and rural markets, along with a lack of overall market transparency. Our China In-Depth solution allows you to:

QUANTIFY

Accurately quantify market potential for your pipeline assets in China

UNDERSTAND

Understand the commercial impact of new brands, generics and key China market events

STRATEGIZE

Optimize your clinical development and long-term strategies in China